Page 258 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
6. Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295-2306.
7. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1- specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914-921.
8. Salter AI, Rajan A, Kennedy JJ, et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697):eabe2606.
9. Teppert K, Wang X, Anders K, Evaristo C, Lock D, Künkele A. Joining forces for cancer treatment: rrom “TCR versus CAR” to “TCR and CAR”. Int J Mol Sci. 2022;23(23):14563.
10. Obenaus M, Leitão C, Leisegang M, et al. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nat Biotechnol. 2015;33(4):402-407.
11. D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in
multiple myeloma: a European Myeloma Network (EMN) report
within the HARMONY project. J Clin Oncol. 2022;40(29):3406-3418. 12. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International
Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
13. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 4.0. https://www.eortc.be/ services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7. pdf Accessed January 9, 2024.
14. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
15. Adebayo OO, Dammer EB, Dill CD, et al. Multivariant transcriptome analysis identifies modules and hub genes associated with poor outcomes in newly diagnosed multiple myeloma patients. Cancers (Basel). 2022;14(9):2228.
Haematologica | 110 January 2025
250